Stereotaxis to acquire Robocath, terms undisclosed

Stereotaxis (STXS) announced that it has entered into a definitive agreement to acquire Robocath. Stereotaxis estimates that Robocath will contribute approximately $2M in annual revenue during the first year post-acquisition. The acquisition is expected to become breakeven by the third year post-acquisition, supported by commercial and operational synergies. The transaction consideration includes an upfront payment of $20M, and additional contingent payments of up to $25M tied to regulatory and commercial milestones, including FDA clearance of Robocath’s next generation system. Consideration is payable in cash or Stereotaxis common stock, at Stereotaxis’ discretion. The acquisition is subject to customary closing conditions and is expected to close in mid-2026. Upon closing, Robocath will operate as a wholly owned subsidiary of Stereotaxis.